Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S Soloway

Showing results (291-300 of 307) with videos related to

Pageof 31
Sort By:
Cancer|November 15, 1996
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study GroupP F Schellhammer, R Sharifi, N L Block, et al.
Urology|September 25, 1997
Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study GroupP F Schellhammer, R Sharifi, N L Block, et al.
Cancer|November 15, 1985
Buserelin as primary therapy in advanced prostatic carcinomaC A Presant, M S Soloway, S S Klioze, et al.
The Prostate|July 27, 1999
Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study GroupD G McLeod, P F Schellhammer, N J Vogelzang, et al.
The Journal of Urology|February 1, 1979
Comparison of procarbazine, imidazole-carboxamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostateJ D Schmidt, W W Scott, R P Gibbons, et al.
Urology|July 22, 1998
Comparison of goserelin and leuprolide in combined androgen blockade therapyM F Sarosdy, P F Schellhammer, R Sharifi, et al.
The Journal of Urology|June 1, 1979
The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiationG P Murphy, R P Gibbons, D E Johnson, et al.
Transactions of the American Association of Genito-Urinary Surgeons|January 1, 1978
The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiationG P Murphy, R P Gibbons, D E Johnson, et al.
The Journal of Urology|June 1, 1981
A comparison of hydroxyurea, methyl-chloroethyl-cyclohexy-nitrosourea and cyclophosphamide in patients with advanced carcinoma of the prostateS A Loening, W W Scott, J deKernion, et al.
The Journal of Urology|May 1, 1981
Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostateM S Soloway, J B deKernion, R P Gibbons, et al.
Pageof 31

Showing results (291-300 of 307) with videos related to

Sort By:
Pageof 31
Cancer|November 15, 1996
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study GroupP F Schellhammer, R Sharifi, N L Block, et al.
Urology|September 25, 1997
Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study GroupP F Schellhammer, R Sharifi, N L Block, et al.
Cancer|November 15, 1985
Buserelin as primary therapy in advanced prostatic carcinomaC A Presant, M S Soloway, S S Klioze, et al.
The Prostate|July 27, 1999
Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study GroupD G McLeod, P F Schellhammer, N J Vogelzang, et al.
The Journal of Urology|February 1, 1979
Comparison of procarbazine, imidazole-carboxamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostateJ D Schmidt, W W Scott, R P Gibbons, et al.
Urology|July 22, 1998
Comparison of goserelin and leuprolide in combined androgen blockade therapyM F Sarosdy, P F Schellhammer, R Sharifi, et al.
The Journal of Urology|June 1, 1979
The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiationG P Murphy, R P Gibbons, D E Johnson, et al.
Transactions of the American Association of Genito-Urinary Surgeons|January 1, 1978
The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiationG P Murphy, R P Gibbons, D E Johnson, et al.
The Journal of Urology|June 1, 1981
A comparison of hydroxyurea, methyl-chloroethyl-cyclohexy-nitrosourea and cyclophosphamide in patients with advanced carcinoma of the prostateS A Loening, W W Scott, J deKernion, et al.
The Journal of Urology|May 1, 1981
Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostateM S Soloway, J B deKernion, R P Gibbons, et al.
Pageof 31